Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

On Friday, Eli Lilly And Co LLY released new results from Ebglyss’s (lebrikizumab-lbkz) long-term study, ADjoin. New data shows Ebglyss achieved deep and sustained response for patients with ...

Like many pharma stocks, Eli Lilly (NYSE: LLY ... Lilly expects data readouts this year from a phase 3 trial of retatrutide, a weight loss candidate it's suggested may be even more effective ...